Catalent Can't Duck IP Suit Over Epilepsy Drug Vimpat
A Kentucky federal judge on Monday denied a bid to dismiss UCB's suit against Catalent Pharma Solutions over its importation of the active ingredient in anti-epileptic drug Vimpat, saying the complaint...To view the full article, register now.
Already a subscriber? Click here to view full article